Journal of Clinical Virology - Volume 82 - Supplement 1 - September 2016

146 / 152

S142 Abstracts / Journal of Clinical Virology 82S (2016) S1–S142
Abstract no: 6
Presentation at ESCV 2016: Poster 246
EBV and numerous associated diseases
G. Glady
European Bioimmun(g)en Medicine Association
(EBMA), France
EBV is probably the most spread virus within the human race,
because about 90% of the general adult population are carriers of it.
The biological diagnosis is at present codified very well and
allows to detect easily the “healthy carriers”, those which are nor-
mally immunized.
It turns out nevertheless, that those are not necessarily the most
numerous, and that there is a large number of patients disturbed
by the presence of the virus, and which are going to develop or a
persistent primary infection or a so-called reactivation.
In both cases aforesaid it is not any more question about some
process of infectious nature, but about various disturbances affect-
ing the immune system of some different way in continuation of
the interactions with the virus.
The purpose of this to-day presentation is going to show exactly
to what extent the EBV is capable, by using the immunitary
resources of the patient to favor the development of a large number
of diverse pathological disorders, which are involved in the genesis
of a set of diseases being responsible of often very different noso-
logical frames, and whose evolution will be favorably influenced by
EBV neutralization.
This last one can be realized by applying a therapy with an epi-
genetic modulation by means of micro-RNAs, those of the virus but
of the host-cell too, used within the framework of a sub-lingual
immunotherapy.
Abstract no: 8
Presentation at ESCV 2016: Poster 247
Investigation of malignancy associated with
EBV (Epstein-barr virus) in paediatric patients
with liver transplant
M. Colak ∗ . Altay Eksi Bozbulut
B. Dalgic , I. Fidan , S. Ozkan , G. Bozdayi
1 Gazi University Faculty of Medicine, Department of
Medical Microbiology, Ankara, Turkey
2 Gazi University Faculty of Medicine, Department of
Pediatric Gastroenterology, Ankara, Turkey
3 Gazi University Faculty of Medicine, Department of
Public Health, Ankara, Turkey
Background: The aim of this retrospective study was investi-
gation of malignancy associated with EBV (Epstein-Barr Virus) and
viral load by real-time polymerase chain reaction (Real-Time PCR)
in paediatric patients with liver transplant.
Material and methods: Thirty-two paediatric patients that
applied from Gazi University Faculty of Medicine, Department of
Paediatric Gastroenterology who were liver transplant between
March 2014 and January 2016. EBV VCA IgM, VCA IgG, EBNA IgM,
EBNA IgGve EA IgGantibodieswere investigatedby Enzyme-Linked
Immunosorbent Assay (ELISA) (DIA PRO Milano, Italy) method in
clinical samples of patients that required of serological analyses.
Serological profiles of patients were determined and EBV DNA was
investigated quantitatively by Real-Time PCR. DNAs were extracted
by “Spin-Column” method (High Pure Viral Nucleic Acid Kit, Roche,
Germany). Isolated DNAs were amplified by Real-Time PCRmethod
in LightCycler 2.0 (Roche, Germany) device and the results were
evaluated quantitatively.
Results: In our study 18 females (%56.3), 14 males (%43.7) pae-
diatric patients ages between 1 and 18 years were investigated.
EBV DNAwas positive for %15.6 (5/32) of patients by Real-Time PCR
method. EBVDNA andVCA IgMpositivitywas not detected simulta-
neously. The patients that EBV DNA detected were diagnosed with
Biliary atresia, Progressive familial intrahepaticcholestasis (PFIC),
Wilson, Chronic liver failure and all patients had liver transplanta-
tion. There was no rejection in EBV-positive patients and Burkitt’s
lymphoma developed in one positive patient (1/5). ALT, AST, GGT
values were within normal limits in EBV DNA positive patients. EBV
DNApositive patientswere treatedwith acyclovir, ganciclovir or val
ganciclovir without changing immunosuppressive therapy. One of
the EBV positive five patients, have not participated in the treat-
ment process and have not applied again to hospital; one patient
died due to Burkitt’s lymphoma; for the remaining three patients,
it was observed that the process was continuing with therapy and
recurrent infections. It is revealed that the most common symp-
toms are fever, vomiting, diarrhea and tonsillitis in EBV positive
patients. EBV DNA was found ≥104 copies/ml for the 80% (4/5) of
the studied samples and 20% (1/5) had ≥10 5 copies/ml.
Conclusion: EBV infection is a high risk factor in immuno-
suppressive patients especially transplantation patients, EBV was
important for these patients’ follow-up and prognosis. Monitor-
ing EBV DNA levels closely with Real-Time PCR methods is helpful
for evaluating the changes in the clinical course and early diagno-
sis. The patient, who was diagnosed with Burkitt’s lymphoma, had
high viral load (≥105 copies/ml); therefore, in immunosuppress-
ive patients that were detected high levels of EBV DNA, Burkitt’s
lymphoma disease should be considered.